Glaxo/THRX' Drug Gets FDA Nod - Analyst Blog

By
A A A

GlaxoSmithKline ( GSK ) and partner Theravance, Inc. ( THRX ) received a boost with the U.S. Food and Drug Administration (FDA) approving Anoro Ellipta. The FDA cleared Anoro Ellipta (once daily) as a long-term maintenance therapy for airflow obstruction in patients suffering from chronic obstructive pulmonary disease (COPD) including chronic bronchitis and/or emphysema.

Anoro Ellipta is a combination of a long-acting muscarinic antagonist/LAMA (GSK573719 or umeclidinium bromide/UMEC) and a long-acting beta2 agonist/LABA (vilanterol/VI).

The U.S. approval of Anoro Ellipta was not surprising considering that the Pulmonary-Allergy Drugs Advisory Committee recommended the approval of the drug in Sep 2013. The approval triggers a milestone payment of $30 million from Theravance to Glaxo. Glaxo will receive a further payment of $30 million following the product launch. The launch activities related to Anoro Ellipta are expected to start from the first quarter of 2014.

We remind investors that in Oct 2013 Glaxo and Theravance had launched another COPD drug, Breo Ellipta, in the U.S.

Anoro Ellipta and Breo Ellipta, if successfully commercialized, will compensate for the loss of revenues once Advair - one of Glaxo's highest revenue grossers - goes generic. The product generated sales of $3.9 billion in the first nine months of 2013, accounting for almost 25% of the company's Pharmaceuticals and Vaccines segment revenues.

Both Glaxo and Theravance carry a Zacks Rank #3 (Hold). Some better-ranked stocks include Jazz Pharmaceuticals ( JAZZ ) and Actelion Ltd. ( ALIOF ). Both companies hold a Zacks Rank #1 (Strong Buy).



ACTELION LTD (ALIOF): Get Free Report

GLAXOSMITHKLINE (GSK): Free Stock Analysis Report

JAZZ PHARMACEUT (JAZZ): Free Stock Analysis Report

THERAVANCE INC (THRX): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: Investing , Business , Stocks

Referenced Stocks: ALIOF , GSK , JAZZ , THRX

Zacks.com

Zacks.com

More from Zacks.com:

Related Videos

Stocks

Referenced

Most Active by Volume

270,887,127
    $93.89 unch
225,243,115
  • $40.93 ▼ 2.74%
135,900,109
  • $47.52 ▲ 1.80%
89,467,924
  • $5.35 ▼ 1.11%
85,105,358
  • $16.95 ▼ 0.53%
80,748,539
  • $39.80 ▼ 4.21%
68,491,586
  • $3.57 ▼ 1.79%
62,097,356
  • $100.96 ▼ 0.82%
As of 9/19/2014, 04:15 PM

Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com